• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44.古塞库单抗治疗中度至重度活动性溃疡性结肠炎患者的糖皮质激素节省效应：3期QUASAR维持研究至第44周的结果
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 10):9-10.
2
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.古塞库单抗治疗中度至重度活动性溃疡性结肠炎患者（QUASAR）：3期双盲、随机、安慰剂对照诱导和维持研究
Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17.
3
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.古塞单抗治疗中重度活动性溃疡性结肠炎患者：QUASAR 期 2b 诱导研究。
Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1.
4
The Efficacy of Maintenance Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase Inhibitor History.
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 10):5-6.
5
Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study.
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 10):12-13.
6
The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study.古塞库单抗作为中度至重度活动性溃疡性结肠炎患者维持治疗的疗效和安全性：3期QUASAR维持研究结果
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 6):8-9.
7
Guselkumab: A New Therapeutic Option for the Treatment of Moderately to Severely Active Ulcerative Colitis.
Ann Pharmacother. 2025 Sep;59(9):862-867. doi: 10.1177/10600280241305441. Epub 2025 Jan 12.
8
The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.古塞库单抗诱导治疗中重度活动性溃疡性结肠炎患者的疗效和安全性：2b期QUASAR研究第12周结果
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):12.
9
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.古塞库单抗联合戈利木单抗与古塞库单抗或戈利木单抗单药治疗溃疡性结肠炎患者的疗效比较（VEGA）：一项随机、双盲、对照、2期概念验证试验
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1.
10
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.瑞莎珠单抗对中度至重度活动性溃疡性结肠炎患者的糖皮质激素节省作用、疗效及安全性
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjaf025.

引用本文的文献

1
Network Meta-Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis.网状Meta分析：生物疗法和小分子药物作为溃疡性结肠炎维持治疗的疗效
Aliment Pharmacol Ther. 2025 Jul;62(1):4-21. doi: 10.1111/apt.70209. Epub 2025 May 23.

Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44.

出版信息

Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 10):9-10.

PMID:39896693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11784576/
Abstract
摘要